Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19965197 | 0.87 | CYP11B2 (0.54) | CYP11B2MKNK1FFAR4CYP11B1MAP3K5 | |
| SCHEMBL19965065 | 0.85 | MAP4K4 (0.42) | CYP11B2FFAR4LMNATDP1HTT | |
| SCHEMBL19965120 | 0.82 | SMN1; SMN2 (0.46) | CYP11B2MKNK1FFAR4LMNATDP1 | |
| SCHEMBL19965178 | 0.80 | PRKCA (0.46) | CYP11B2ADAM17MAP3K5 | |
| SCHEMBL19965013 | 0.80 | CYP11B2 (0.43) | CYP11B2CYP11B1MAP3K5 | |
| SCHEMBL19965213 | 0.79 | LMNA (0.37) | CYP11B2FFAR4LMNATDP1HRH4 | |
| SCHEMBL19965112 | 0.78 | FFAR4 (0.36) | CYP11B2MKNK1FFAR4LMNATDP1 | |
| SCHEMBL19965105 | 0.77 | HRH4 (0.42) | CYP11B2MKNK1FFAR4LMNATDP1 | |
| SCHEMBL21124472 | 0.72 | FFAR4 (0.60) | CYP11B2MKNK1FFAR4HRH4CYP11B1 | |
| SCHEMBL19965074 | 0.71 | MKNK1 (0.35) | CYP11B2MKNK1FFAR4LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183231-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | Valo Health, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230183231-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | Valo Health, LLC | 2023-06-15 | — | — | US | disclosed |
| US-11548886-B2 | Monocyclic compounds useful as GPR120 modulators | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210101896-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | Valo Health, LLC | 2021-04-08 | — | — | US | disclosed |
| US-10800773-B2 | Monocyclic compounds useful as GPR120 modulators | INTEGRAL HEALTH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190202821-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | Valo Health, LLC | 2019-07-04 | — | — | US | disclosed |
| WO-2018049324-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | NUMERATE, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548886-B2 | Monocyclic compounds useful as GPR120 modulators | GPR119, GPR180, GPR65 | CYP11B2 571/4885MKNK1 1863/4885FFAR4 32/4885 |
| US-10800773-B2 | Monocyclic compounds useful as GPR120 modulators | GPR119, GPR180, GPR65 | CYP11B2 571/4885MKNK1 1863/4885FFAR4 32/4885 |
| US-20210101896-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | GPR119, GPR180, GPR65 | CYP11B2 571/4885MKNK1 1863/4885FFAR4 32/4885 |
| US-20190202821-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | GPR119, GPR180, GPR65 | CYP11B2 571/4885MKNK1 1863/4885FFAR4 32/4885 |
| US-20230183231-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | GPR119, GPR180, GPR65 | CYP11B2 571/4885MKNK1 1863/4885FFAR4 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.